Literature DB >> 698971

Some comments on the necessity of receptor determination in human breast cancer.

W Jonat, H Maass.   

Abstract

Estrogen receptors (ER's) were determined by agar gel electrophoresis in 105 human mammary tumor biopsies. Fifty-three tumor specimens revealed measurable amounts of receptor, and 64% of these patients showed an objective remission after endocrine treatment. If we also include cases with partial remission, previous response, and arrested growth but no actual remission, the benefit rate increases to 87%. The corresponding percentage in the ER-negative groups is 13%. In a retrospective study of 42 patients with human breast cancer, a correlation between ER finding and remission rate after chemotherapy was found. Of the ER-negative patients, 71% showed an objective remission after polychemotherapy, whereas only 43% of the ER-positive cases revealed such remission. The presented data are discussed with special regard to their clinical relevance.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 698971

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

1.  Oestrogen receptors and response to cytotoxic chemotherapy in advanced breast cancer.

Authors:  R D Rubens; R J King; S Sexton; M J Minton; J L Hayward
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

2.  The activity of phosphohexose isomerase in primary breast carcinomas and response to chemotherapy in patients with metastatic disease.

Authors:  I Mitchell; N Deshpande; R Millis; R D Rubens
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

3.  Estrogen-receptor status and response to chemotherapy in early and advanced breast cancer.

Authors:  G Bonadonna; P Valagussa; G Tancini; G Di Fronzo
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

4.  Relation of estrogen and/or progesterone receptor content of breast cancer to patient outcome following adjuvant chemotherapy.

Authors:  B Fisher; C K Redmond; D L Wickerham; H E Rockette; A Brown; J Allegra; D Bowman; D Plotkin; J Wolter
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872

Review 5.  Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action.

Authors:  C K Osborne; A Wakeling; R I Nicholson
Journal:  Br J Cancer       Date:  2004-03       Impact factor: 7.640

6.  MDA435/LCC6 and MDA435/LCC6MDR1: ascites models of human breast cancer.

Authors:  F Leonessa; D Green; T Licht; A Wright; K Wingate-Legette; J Lippman; M M Gottesman; R Clarke
Journal:  Br J Cancer       Date:  1996-01       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.